(e)-N-{3- [1-(8-fluoro-11H-10-oxa-1-aza-dibenzo [a,d] cycl0hepten-5ylidene)-propyl]-phenyl }-methynsulfon amide as glucocorticoid receptor modulator for the treatment of rheumatoid
Details for Australian Patent Application No. 2009204155 (hide)
International Classifications
Event Publications
17 June 2010 PCT application entered the National Phase
PCT publication WO2009/089312 Priority application(s): WO2009/089312
8 July 2010 Corrigenda
PCT applications that have entered the National Phase - Name Index Under the name Eli Lilly and Company, Application No. 2009204155, under INID (54) correct the title to read (E)-N-{3- [1-(8-Fluoro-11H-10-oxa-1-aza-dibenzo [a,d] cyclohepten5ylidene)-propyl]-phenyl }-methynsulfon amide as glucocorticoid receptor modulator for the treatment of rheumatoid
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser